The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer
Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.
Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC
February 7th 2022Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.
Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC
February 7th 2022Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.
Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC
Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.
Sugemalimab Plus Chemo Significantly Improves Survival in Frontline Stage IV NSCLC
The addition of the PD-L1 inhibitor sugemalimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in the frontline treatment of patients with stage IV non–small cell lung cancer.
Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA NSCLC, Irrespective of PD-L1 Expression
Adjuvant treatment with pembrolizumab led to a statistically significant and clinically meaningful improvement in disease-free survival vs placebo in patients with stage IB to IIIA non–small cell lung cancer following resection, regardless of PD-L1 expression, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.
Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC
January 4th 2022The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.
FDA Grants Fast Track Status to Novel Gene Therapy Plus Pembrolizumab for Late-Stage NSCLC
The FDA has granted a fast track designation to a combination comprised of the immunogene therapy quaratusugene ozeplasmia and pembrolizumab for use in select patients with late-stage non–small cell lung cancer.
Real-World Data Underscores Efficacy of Durvalumab in NSCLC
December 17th 2021Real-world data from the PACIFIC-R trial evaluating durvalumab following chemoradiotherapy in patients with stage III, unresectable non–small cell lung cancer provide evidence supporting the agent’s efficacy in this population, solidifying its role as a standard-of-care treatment
Community Perspectives in Non–Small Cell Lung Cancer
December 8th 2021In this clinical case review, a panel of community experts discusses the management of immunotherapy in patients with NSCLC, reflects on factors affecting treatment selection and sequencing, and examines the evolving landscape of immunotherapy-based treatment approaches.
Academic Perspectives in Non-Small Cell Lung Cancer
December 1st 2021In this clinical case review, academic experts share insights into the disease management of patients with NSCLC, discuss factors impacting treatment selection and sequencing strategies, and evaluate the evolving landscape of immunotherapy-based regimens.
Approaches Under Study to Prolong Immunotherapy Response in Lung Cancer
November 16th 2021Luis E. Raez, MD, FACP, FCCP, discusses frontline immunotherapeutic options in NSCLC, management strategies for patients with stage III disease, targeted approaches for patients with EGFR- and ALK-positive NSCLC, and how the field of SCLC is navigating newly available therapies.
Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC
T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.
Neoadjuvant Nivolumab Plus Chemo Significantly Improves EFS in Resectable NSCLC
The addition of nivolumab to chemotherapy resulted in a statistically significant and clinically meaningful improvement in event-free survival vs chemotherapy alone, when administered prior to surgery in patients with resectable stage IB to IIIA non–small cell lung cancer.
Examining New Approaches to Management of Immune-Related AEs in Lung Cancer
With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.